It's been more than 4 years since the first biosimilar Zarxio was approved in the U.S. Zarxio, developed by Sandoz, a Novartis division, is a biosimilar version of Amgen Inc.'s (AMGN) Neupogen, and it received the regulatory nod in the U.S. in March 2015.
from RTT - Biotech https://ift.tt/37lPpHr
via IFTTT
No comments:
Post a Comment